A little more than a month after World AIDS Day 2019, COVID-19 started to impact our HIV programs in Asia as countries like Cambodia, Thailand and Vietnam began quarantine. Community testing ground to a halt. People living with HIV worried about access to their medications. HIV pre-exposure prophylaxis (PrEP) enrollment slowed. COVID-19 testing diverted laboratories from HIV services. By March 2020, the rest of the world was equally impacted. FHI 360’s HIV programs were determined to continue serving people, but there were deep concerns. We were not alone, of course; the global HIV community was facing COVID-19 together. But with so much uncertainty, we wondered: Would COVID-19 substantially set back hard-won gains toward epidemic control? Did we have the tools in hand, or could we develop the tools, to weather this crisis?
We have come a long way from the haunting, early days of the HIV pandemic when hopelessness characterized the situation for children living with HIV. Without treatment available, approximately half of those children were destined to die before their second birthday. The global public health community did not know if it could halt transmission of HIV from mother to child. There were no effective, child-friendly formulations of antiretroviral therapy (ART).